CD274 and esophageal squamous cell carcinoma: These data led to the approval of nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab for first-line treatment of patients with advanced or metastatic ESCC and a PD-L1 expression of 1% or higher.